We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · January 11, 2022

T-DM1 for Patients With NSCLC Positive for HER2 Exon-20 Insertion Mutations

European Journal of Cancer


Additional Info

Disclosure statements are available on the authors' profiles:

European Journal of Cancer
Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations
Eur. J. Cancer 2022 Feb 01;162(xx)99-106, E Iwama, Y Zenke, S Sugawara, H Daga, M Morise, N Yanagitani, T Sakamoto, H Murakami, J Kishimoto, S Matsumoto, Y Nakanishi, K Goto, I Okamoto

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading